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What determines the phenotypic identity of a cell is the 
expression of a particular set of genes in space and time. 
Such selective gene expression patterns are achieved 
through highly choreographed interactions between 
various DNA elements and several multi-protein com-
plexes. Th e principle DNA elements responsible for cell 
type-specifi c gene expression are the enhancer sequences. 
A recent study [1] now reveals that cancer cells exploit 
enhancers to reprogram global gene expression in their 
favor.
Enhancers as distal gene regulatory elements
Enhancers are short DNA sequences with binding sites 
for several transcription factors that are largely 
responsible for specifi city of gene expression patterns in a 
given cell. First discovered through studies of the simian 
virus 40 (SV40) genome [2], enhancers can remotely 
regulate transcription from thousands of base pairs away 
in either direction or orientation relative to their target 
genes. Although these molecular characteristics defi ne 
enhancer function, enhancer elements can also be 
identifi ed by specifi c features of the chromatin in which 
they are embedded. Th ese include variations in chromatin 
compaction, which can be monitored by enzymes that 
digest the DNA (such as DNase I), and combinations of 
histone modifi cations, such as histone 3 lysine 4 mono-
methylation (H3K4me1), a seemingly ubiquitous marker 
of enhancers, and more specifi c acetylation (ac) and 
methylation of histones H3 and H4 [3]. Th e epigenetic 
marks are established through recruitment of histone-
modifying enzymes by the transcription factors that are 
bound to the enhancers. As a result, a combinatorial 
pattern of histone modifi cations may not only identify 
enhancers but also provide a measure of the level of 
enhancer functional activity. For instance, presence of 
H3K4me1 with H3K27ac probably indicates an active 
enhancer whose target gene(s) is currently expressed. 
Loss of H3K4me1 or co-presence of H3K4me1 and a 
repressive histone mark such as H3K27me3 suggests an 
inactive enhancer whose target gene is being repressed. 
How enhancers locate and interact with promoters at a 
distance remains an area of active investigation but 
current evidence suggests that architectural looping of 
chromatin, facilitated in part by cohesin and CCCTC-
binding factor (CTCF), is required to bring the enhancers 
and promoters to close physical proximity of each other. 
Once juxtaposed, the Mediator co-activator complex 
coordinates functional interactions between enhancer-
bound transcription factors and the promoter-bound 
basal transcription machinery, including RNA 
polymerase II [4].
Redefi ning long-distance relationships in cancer
Previous studies have provided evidence that regions of 
the genome that are associated with the predisposition to 
cancer but are far from any annotated gene loci may 
coincide with enhancers [5]. A comprehensive recent 
study by Akhtar-Zaidi et al. [1] has now revealed that, in 
colon cancer, enhancer elements are indeed critical in 
promoting an oncogenic gene expression program on a 
cellular scale and are signifi cantly associated with genetic 
risk variants. Using chromatin immunoprecipitation 
com bined with next-generation sequencing (ChIP-seq), 
the authors [1] determined the genome-wide distribution 
of H3K4me1 in normal colon epithelia and nine 
colorectal cancer (CRC) cell lines that represent diff erent 
stages of cancer progression, including metastasis. 
Interest ingly, the overall distributions of H3K4me1 in 
normal colon and cancer cells were more similar to each 
other than either are to normal or cancer cells derived 
from other tissue types, indicating that, to some degree, 
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cancer cells retain the epigenetic identity of the tissue 
from which they originally arose. Nonetheless, in cancer 
cells thousands of regions either gained or lost H3K4me1 
when compared with normal colon cells. Th ese regions 
were termed variant enhancer loci (VELs), a limited 
number of which were confi rmed to indeed have 
enhancer activity in a standard assay. Th e prevalence of 
VELs is even more widespread, as the authors estimate 
that 40 to 60% of VELs remain to be discovered [1]. 
Despite the large number of VELs, only approximately 
200 were common to all nine CRC cell lines, indicating a 
level of heterogeneity in aff ected enhancers depending on 
the cancer cell line. Th e VELs that were lost in colon 
cancer cells were found to be present most often in 
normal colon epithelium compared to non-colon normal 
or cancer cells. In contrast, the gained VELs in CRCs 
were also found commonly in other cell lines. Th is is 
consistent with a model in which colon cancer cells have 
dediff erentiated from a colon-specifi c to a more generic 
phenotype.
Th e VELs also showed other epigenetic changes, 
including acetylation and deacetylation of H3K27 in a 
large fraction of gained and lost VELs, respectively, as 
well as altered sensitivity to DNase I. Th ese chromatin 
alterations suggest changes in enhancer activity and 
expression of the associated gene(s). To determine whether 
this is the case, the authors [1] had fi rst to determine 
which VELs are associated with which genes - not a 
trivial task considering the molecular characteristics of 
enhancers. Taking multiple bioinformatics approaches 
and performing statistical gymnastics, they developed an 
eff ective algorithm for assigning VELs to specifi c genes, 
which takes into account, among other information, gene 
expression levels and the assumption that CTCF binding 
sites block enhancer-promoter interactions. Using the 
algorithm, the authors [1] found that the genes that were 
linked to gained VELs were expressed at higher levels in 
CRCs than normal cells and also gained H3K27ac and 
became hypersensitive to DNase I. Th e converse was true 
for genes with lost VELs. And the more VELs were linked 
to a gene, the more pronounced was the gene expression 
diff erence between normal and CRC cells. Th e VEL-
linked genes were also more likely to be aberrantly 
expressed in primary tumors than were genes not linked 
to VELs. It is conceivable that the expression of the VEL-
linked genes could also serve as a prognostic signature, 
but this was not tested in the report [1].
To provide further evidence that the VELs contribute 
to CRC development and/or progression, the authors [1] 
showed that the VELs, especially those that are turned off  
in CRC cells, are signifi cantly associated with single 
nucleotide polymorphisms (SNPs) that have been shown 
through genome-wide association studies to confer 
increased risk of developing CRC. In some instances, the 
SNPs overlapped physically with VELs. Th e SNPs may 
aff ect binding of transcription factors to the enhancers 
and modulate the enhancers’ eff ects on their target gene 
expression. Taking all the data together, the evidence 
supports the view that improper usage of enhancer 
elements, especially the silencing of tissue-specifi c 
enhancers, can promote a carcinogenic gene expression 
program.
It will be interesting to determine how epigenetic 
changes at enhancers are achieved in cancer cells. Th ese 
epigenetic changes indicate alterations in targeting of 
trans cription factors and cofactors that establish the 
epigenetic marks at enhancers in the fi rst place. One 
important factor is the p300 lysine acetyltransferase 
(KAT), the binding of which has also been shown to 
predict enhancer sequences [3,6]. Th e p300 KAT and its 
closely related paralog CBP acetylate H3K27 (in addition 
to other lysine residues). So it is possible that redistri bu-
tion of H3K27ac from lost to gained VELs could at least 
be partly due to redistribution of p300/CBP KATs. 
Notably, signifi cant redistribution of p300/CBP with 
eff ects on another histone acetylation site implicated in 
the cancer phenotype, H3K18 [7,8], is also required for 
virus-mediated oncogenic transformation [9]. Similar 
relocalization scenarios could apply in principle to other 
epigenetic enzymes and histone modifi cations, including 
H3K4me1, resulting in epigenetic reprogramming of 
cancer cells. Because histone-modifying enzymes generally 
do not bind directly to DNA, their redistri bution would 
depend on their interactions with the sequence-specifi c 
DNA binding proteins that recruit them. Intriguingly, 
mutations in epigenetic enzymes, including p300 and 
CBP, that could modify their enzymatic activities or 
interactions with other proteins are increasingly reported 
in cancer [10]. As Akhtar-Zaidi et al. [1] suggest, the 
VELs may in fact represent the culmination of the 
complex interactions between genetic and epigenetic 
elements that redefi ne which enhancers are turned on or 
off  in cancer.
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